{
  "ticker": "JNJ",
  "target_date": "2025-07-25",
  "actual_date": "2025-07-25",
  "collected_at": "2025-12-08T12:03:37.648844",
  "price": {
    "open": 167.45,
    "high": 167.58,
    "low": 165.17,
    "close": 166.0195770263672,
    "volume": 6254900,
    "change_1d_pct": -0.74,
    "change_7d_pct": 2.14,
    "change_30d_pct": 8.4
  },
  "technicals": {
    "rsi_14": 76.93,
    "sma_20": 157.7,
    "sma_50": 153.53,
    "macd": 3.797,
    "macd_signal": 2.68,
    "macd_histogram": 1.117,
    "bb_upper": 169.1,
    "bb_lower": 146.29,
    "price_vs_sma20_pct": 5.28,
    "price_vs_sma50_pct": 8.13,
    "volume_ratio": 0.72
  },
  "fundamentals": {
    "market_cap": 488876113920,
    "pe_ratio": 19.58615,
    "forward_pe": 19.142689,
    "price_to_book": 6.1587553,
    "price_to_sales": 5.305279,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.36,
    "pct_from_52w_low": 44.24
  },
  "macro": {
    "spy": {
      "price": 635.34,
      "change_1d_pct": 0.42,
      "change_7d_pct": 1.44
    },
    "vix": {
      "level": 14.93,
      "signal": "LOW_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.39
    },
    "dollar_index": {
      "level": 97.65
    },
    "gold": {
      "price": 3334.0
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Fidelity Strategic Dividend & Income Fund Q2 2025 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1753477200,
      "summary": "Fidelity Investments highlights strong Q2 gains in convertibles and infrastructure. See how tactical shifts shaped results. Explore the full fund update.",
      "url": "https://finnhub.io/api/news?id=da9a47446368a5deb2b7e49b3d1fb01a4272e75100efada772f083753847fbea"
    },
    {
      "headline": "Fidelity Balanced Fund Q2 2025 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1753476000,
      "summary": "Fidelity Investments reports a 2.74% Q1 loss for its Balanced Fund. See how equity picks and bond strategy shaped results. Review the full update.",
      "url": "https://finnhub.io/api/news?id=a8c74b2643fa75761f001aefff25b82d418a05756262be856f32dae651db4c17"
    },
    {
      "headline": "AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate",
      "source": "Yahoo",
      "datetime": 1753376923,
      "summary": "AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients. MG is a chronic autoimmune disorder that causes muscle weakness a",
      "url": "https://finnhub.io/api/news?id=3517e509b2206d2e92358226a89c67b92774ea23c8c87e3935af1edabdaef0c8"
    },
    {
      "headline": "Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term",
      "source": "Yahoo",
      "datetime": 1753365001,
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=fa5cbdac47356c7f9027098e504789c3fa65f66d00a95158bd197db897fb3dd2"
    },
    {
      "headline": "J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?",
      "source": "Yahoo",
      "datetime": 1753363380,
      "summary": "JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.",
      "url": "https://finnhub.io/api/news?id=b0c003928b0c797247e577d10b0d8ddb4ff152a4becfbdf922189047918cab24"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "10-Q",
      "date": "2025-07-24",
      "description": "jnj-20250629.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000178/jnj-20250629.htm"
    },
    {
      "form": "13F-HR",
      "date": "2025-07-22",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000367/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-07-18",
      "description": "xslF345X05/wk-form4_1752869553.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000172/xslF345X05/wk-form4_1752869553.xml"
    },
    {
      "form": "8-K",
      "date": "2025-07-16",
      "description": "jnj-20250716.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/jnj-20250716.htm"
    },
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760336.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000156/xslF345X05/wk-form4_1749760336.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}